




Supplemental Figure 1. iPSC characterization and QC. A-D. iPSC characterization for *MAPT* IVS10+16 donor lines and isogenic controls. Each iPSC line used in the study was verified by Sanger sequencing. Karyotyping was performed to confirm chromosomal stability. Immunocytochemistry was performed to confirm expression of pluripotency markers. A-B. Isogenic pair, FTD1. A. GIH36, *MAPT* IVS10+16. B. GIH36C2Δ1D01, *MAPT* WT. C-D. Isogenic pair, FTD2. C. GIH178C1, *MAPT* IVS10+16. D. GIH178C1Δ2A10, *MAPT* WT. E. PCA for RNA sequencing of *MAPT* IVS10+16 and isogenic control iMGLs.